Aldeyra's reproxalap receives a third FDA rejection for dry eye disease as inconsistent trial results undermine efficacy case
The third CRL in three years cites a lack of substantial evidence of efficacy for the RASP inhibitor eye drop, with the FDA pointing to inconsistent results across trials
